Trials / Completed
CompletedNCT01913431
Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, double blind, active-controlled, randomized, parallel group study to demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baracle Tab.® | |
| DRUG | Baraclude Tab.® |
Timeline
- Start date
- 2013-09-12
- Primary completion
- 2015-11-06
- Completion
- 2015-11-06
- First posted
- 2013-08-01
- Last updated
- 2017-08-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01913431. Inclusion in this directory is not an endorsement.